← All trials
NCT06333821
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2024
- Primary completion
- Apr 1, 2030
- Completion date
- Apr 1, 2030
- First posted
- Mar 27, 2024
- Last posted
- Mar 27, 2024
- Enrollment
- 460
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Biotech Pharmaceutical Co., Ltd.Lead sponsor
- Jiangxi Maternal and Child Health HospitalOfficial
- North Sichuan Medical UniversityOfficial
- First People's Hospital of FoshanOfficial
- Southern Medical UniversityOfficial
- Fujian Medical UniversityOfficial
- Guangxi Medical UniversityOfficial
- Anhui Province Cancer HospitalOfficial
- Hebei UniversityOfficial
- Shaanxi Provincial People's HospitalOfficial
- Shengjing HospitalOfficial
- Shenzhen UniversityOfficial
- University of South ChinaOfficial
- Jiao Tong UniversityOfficial
- Central South UniversityOfficial
- Jiao Tong UniversityOfficial
- Jiao Tong UniversityOfficial
- Central South UniversityOfficial
- China Medical UniversityOfficial
- Shanxi Medical UniversityOfficial
- Nanchang UniversityOfficial
- Nanchang UniversityOfficial
- Dalian Medical UniversityOfficial
- Dalian Medical UniversityOfficial
- Sichuan UniversityOfficial
- Inner Mongolia Medical UniversityOfficial
- Qingdao UniversityOfficial
- Cancer Hospital of Yunnan provincealOfficial
- Harbin Medical UniversityOfficial
- Henan Medical UniversityOfficial
- LanZhou UniversityOfficial
- Xiamen UniversityOfficial
- Xiamen UniversityOfficial
- Jilin UniversityOfficial
- Peking UniversityOfficial
- Peking UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.